Patents Assigned to GLACTONE PHARMA DEVELOPMENT AB
  • Sulfonamide analogues of galiellalactone
    Patent number: 10781197
    Abstract: Disclosed are sulfonamide analogues of galiellactone of formula (I) as STAT3-inhibitors for use in the treatment of a STAT3 signaling related disorder, e.g. solid cancers, hematological cancers, benign tumors, hyperproliferative diseases, inflammations, autoimmune diseases, graft or transplant rejections, delayed physiological function of grafts or transplants, neurodegenerative diseases and viral infections. The sulfonamide comprises a cyclic substituent.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: September 22, 2020
    Assignee: GLACTONE PHARMA DEVELOPMENT AB
    Inventors: Martin Johansson, Olov Sterner
  • Tricyclic prodrugs
    Patent number: 10538500
    Abstract: Prodrugs of galiellactone, and derivatives thereof, are provided by reacting the parent compound, e.g. galiellactone, with a thiol. Such drugs may be administered orally to treat cancer and other proliferative diseases.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: January 21, 2020
    Assignee: Glactone Pharma Development AB
    Inventors: Martin Johansson, Olov Sterner
  • Ether analogues of galiellalactone
    Patent number: 10351577
    Abstract: Ether analogues of galiellalactone, methods of preparing the analogues, and use of the analogues in the treatment of cancer are disclosed.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: July 16, 2019
    Assignee: Glactone Pharma Development AB
    Inventors: Johansson Martin, Olov Sterner, Anders Bjartell, Rebecka Hellsten, Zilma Escobar
  • TRICYCLIC PRODRUGS
    Publication number: 20180346435
    Abstract: Prodrugs of galiellactone, and derivatives thereof, are provided by reacting the parent compound, e.g. galiellactone, with a thiol. Such drugs may be administered orally to treat cancer and other proliferative diseases.
    Type: Application
    Filed: August 9, 2018
    Publication date: December 6, 2018
    Applicant: Glactone Pharma Development AB
    Inventors: Martin Johansson, Olov Sterner
  • Tricyclic prodrugs
    Patent number: 10077246
    Abstract: Prodrugs (I) and (Ia) of galiellactone, and derivatives thereof, are provided by reacting the parent compound, e.g. galiellactone, with a thiol. Such drugs may be administered orally to treat cancer and other proliferative diseases.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: September 18, 2018
    Assignee: Glactone Pharma Development AB
    Inventors: Martin Johansson, Olov Sterner
  • ETHER ANALOGUES OF GALIELLALACTONE
    Publication number: 20180155360
    Abstract: Ether analogues of galiellalactone, methods of preparing the analogues, and use of the analogues in the treatment of cancer are disclosed.
    Type: Application
    Filed: June 2, 2016
    Publication date: June 7, 2018
    Applicant: Glactone Pharma Development AB
    Inventors: Johansson Martin, Olov Sterner, Anders Bjartell, Rebecka Hellsten, Zilma Escobar
  • TRICYCLIC PRODRUGS
    Publication number: 20170015644
    Abstract: Prodrugs (I) and (Ia) of galiellactone, and derivatives thereof, are provided by reacting the parent compound, e.g. galiellactone, with a thiol. Such drugs may be administered orally to treat cancer and other proliferative diseases.
    Type: Application
    Filed: March 6, 2015
    Publication date: January 19, 2017
    Applicant: Glactone Pharma Development AB
    Inventors: Martin JOHANSSON, Olov STERNER
  • Tricyclic lactones for treatment of cancer
    Patent number: 9150531
    Abstract: The present invention discloses novel compounds useful for the inhibition of IL-6/STAT signaling and/or PI3K/NF-?B signaling in the treatment of associated diseases or conditions, e.g. cancer. A pharmaceutical composition comprising such novel compounds, its use and a method thereof, is also disclosed.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: October 6, 2015
    Assignee: Glactone Pharma Development AB
    Inventors: Ritha Gidlöf, Martin Johansson, Olov Sterner, Eduardo Muñoz
  • TRICYCLIC LACTONES FOR TREATMENT OF CANCER
    Publication number: 20130310451
    Abstract: The present invention discloses novel compounds useful for the inhibition of IL-6/STAT signaling and/or PI3K/NF-?B signaling in the treatment of associated diseases or conditions, e.g. cancer. A pharmaceutical composition comprising such novel compounds, its use and a method thereof, is also disclosed.
    Type: Application
    Filed: July 18, 2011
    Publication date: November 21, 2013
    Applicant: GLACTONE PHARMA DEVELOPMENT AB
    Inventors: Ritha Gidlöf, Martin Johansson, Olov Sterner, Eduardo Muñoz